Abstract
Although the use of amiodarone for the treatment of atrial fibrillation has increased, reports of its use for the restoration of sinus rhythm have been conflicting.
In a recent prospective, randomized, single-blind, placebo controlled study, we examined the efficacy and safety of amiodarone as initial treatment to restore sinus rhythm in patients with atrial fibrillation of varying duration. We studied 335 patients (169 men, 166 women), aged 27–78 years (mean age 65 ± 10 years), with symptomatic atrial fibrillation, who presented to the emergency room or to our clinic.
Patients randomized to amiodarone (n = 173) received 300 mg intravenously over 1 hour followed by 20 mg/kg over 24 hours. Oral administration was initiated simultaneously at 600 mg/day in 3 divided doses for one week followed by 400 mg/day, in two doses, for three weeks.
Amiodarone was almost twice as likely as placebo to restore sinus rhythm (85% vs. 43%, p < 0.0001). Larger left atrial size and longer duration of atrial fibrillation decreased amiodarone's effectiveness. These factors were also associated with longer duration of treatment before conversion to sinus rhythm.
We observed relatively few and only minor complications despite relatively high doses of amiodarone administered to achieve high serum concentrations.
In conclusion, our findings indicate that amiodarone is an effective and safe antiarrhythmic drug even when administered in large doses. It may be used for the restoration of sinus rhythm when rapid cardioversion is not needed.
Similar content being viewed by others
References
Tieleman RG, Gosselink AT, Crijns HJ, van Gelder IC, van den Berg MP, de Kam PJ, van Gilst WH, Lie KI. Efficacy, safety and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997;79:53-57.
Kerin NZ, Faitel K, Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Arch Intern Med 1996;156:49-53.
GosselinkAT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. Eur Heart J 1995;16:521-528.
Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079-1082.
Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G, Magnani B. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
Donovan KD, Power BM, Hockings BEF. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-697.
Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990;65:679-680.
Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054-1059.
Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: A randomized, controlled study. Chest 2000;117:1538-1545.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vardas, P.E., Kochiadakis, G.E. Amiodarone for the Restoration of Sinus Rhythm in Patients with Atrial Fibrillation. Card Electrophysiol Rev 7, 297–299 (2003). https://doi.org/10.1023/B:CEPR.0000012400.34597.00
Issue Date:
DOI: https://doi.org/10.1023/B:CEPR.0000012400.34597.00